TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

FLUROTECH LTD. ("TEST.H")
[formerly FluroTech Ltd. ("TEST")]
BULLETIN TYPE: Transfer and New Addition to NEX, Symbol Change, Resume Trading
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

Effective at the opening, Monday, October 30, 2023 , the securities of FluroTech Ltd., (the "Company") will resume trading. Further to the Exchange Bulletin dated April 17, 2023 , a news release was issued on October 6, 2023 , announcing that the Company will not be proceeding with its proposed transaction. The transaction contemplated would have constituted a Reverse Takeover as defined under Exchange Policy 5.2.

In accordance with TSX Venture Policy 2.5, the Company has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on Monday, October 30, 2023 , the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Calgary to NEX.

As of October 30, 2023 the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies.

The trading symbol for the Company will change from TEST to TEST.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market.

________________________________________

Right Season Investments Corp. ("LITT")
BULLETIN TYPE: Consolidation
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

Pursuant to a resolution passed by the shareholders of the Company on October 20, 2023 , the Company has consolidated its capital on a seventy (70) old for one (1) new basis. The name of the Company has not been changed.

Effective at the opening October 30, 2023 , the shares of Right Season Investments Corp. will commence trading on TSX Venture Exchange on a consolidated basis. The Company is classified as a 'Financial Services - Investment Companies and Funds' company.

Post - Consolidation

Capitalization: Unlimited shares with no par value of which

2,262,956 shares are issued and outstanding

Escrow Nil shares are subject to escrow

Transfer Agent: Endeavor Trust Corporation

Trading Symbol: LITT ( UNCHANGED )

CUSIP Number: 76658Q206 (NEW)

________________________________________

STALLION URANIUM CORP. ("STUD ")
[formerly STALLION DISCOVERIES CORP. ("STUD ")]
BULLETIN TYPE: Name Change
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

Pursuant to a resolution passed by directors on October 11, 2023 , the Company has changed its name as follows. There is no consolidation of capital.

Effective at the opening October 30, 2023 , the common shares of Stallion Uranium Corp. will commence trading on TSX Venture Exchange, and the common shares of Stallion Discoveries Corp. will be delisted. The Company is classified as a 'Mining' company.

Capitalization: Unlimited shares with no par value of which

109,381,286 shares are issued and outstanding

Escrow: nil common shares

Transfer Agent: Endeavor Trust Corporation

Trading Symbol: STUD ( UNCHANGED )

CUSIP Number: 852919109 ( NEW )

________________________________________

Sucro Limited ("SUG")
B ULLETIN TYPE: New Listing-Shares
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

The Prospectus of Sucro Limited ("Sucro") dated October 19, 2023 (the "Prospectus") has been filed with and accepted by the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Commissions, effective October 23, 2023 , pursuant to the provisions of the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Acts.

The subordinate voting shares (the "SVS") of the Company will be listed and admitted to trading on TSX Venture Exchange, on the effective dates stated below. Each Proportionate Voting Shares ("PVS") is convertible into one hundred (100) SVS. Only the SVS will be listed on the Exchange.

The gross proceeds to be received by the Company for the Offering Are C$15,004,000 , being 1,364,000 SVS at C$11 per SVS, plus up to an additional 15% if over-allotment option is exercised in full.

Listing Date: At the close of business ( 5:01 p.m. EDT ) on Friday, October 27, 2023 .

Commence Date: The SVS will commence trading on TSX Venture Exchange at the opening on Monday, October 30, 2023 , upon confirmation of closing.

The closing of the public offering is scheduled to occur before the market opening on Monday, October 30, 2023 . A further notice will be issued upon receipt of closing confirmation.

For further information, please refer to the Company's Prospectus dated October 19, 2023 available on SEDAR+ and to the Company's news releases dated October 23, 2023 .

Corporate Jurisdiction: Cayman Islands

Capitalization:

Authorized: 490,000,000 SVS and 1,000,000 PVS

with a par value of US$0.0001 per SVS and US$0.001 per PVS, of which

Issued and Outstanding: 6,528,421 SVS and 167,189 PVS (not listed)

Escrowed Securities: 1,153,244 SVS and 167,189 PVS of which

115,324 SVS and 16,718 PVS are released as at the date of this bulletin

Transfer Agent: Odyssey Trust Company

Trading Symbol: SUG

CUSIP Number: G8544S107

The Company is classified as a "Sugar Manufacturing" company (NAICS: 311310).

Company Contact: Stefano D'Aniello, CFO

Company Address: 2020 Ponce de Leon Blvd., Suite 1204 Coral Gables, Florida 33134 USA Company Phone Number: (305) 901-1322

Company Email Address: sdaniello@sucro.us

Company Website: www.sucro.us

________________________________________

THE WELL TOLD COMPANY INC. ("WLCO.H")

roadman investments litt:cc tsxv:litt life science investing Life Science Investing

LITT:CC

Viemed Healthcare Announces Date and Time for Conference Call

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Tuesday, May 7, 2024 at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama.

"We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand HomeMed's business through the strategic partnership," said Viemed Chief Executive Officer Casey Hoyt. "This marks a significant milestone in our ongoing growth strategy, which includes hospital joint ventures and institutional partnerships. We view this transaction as a blueprint that can be replicated nationwide, enhancing care quality while simultaneously creating value for healthcare systems."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Execution of Variation to Facility Agreement with PURE Asset Management, Company to Seek a Sale Transaction

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) advises that today it has signed a variation to its facility agreement with boutique asset manager and existing substantial shareholder PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (PURE or PURE Asset Management) as previously announced to the market on 17 October 2022 (Original PURE Facility).

Keep reading...Show less

Viemed Healthcare, INC. CONSOLIDATED BALANCE SHEETS *(Expressed in thousands of U.S. Dollars, except share amounts)*
	At December 31, 2023		At December 31, 2022
ASSETS
Current assets
Cash and cash equivalents	$	12,839	$	16,914
Accounts receivable, net		18,451		15,379
Inventory		4,628		3,574
Income tax receivable		—		26
Prepaid expenses and other assets		2,449		3,849
Total current assets	$	38,367	$	39,742
Long-term assets
Property and equipment, net		73,579		67,743
Finance lease right-of-use assets		401		—
Operating lease right-of-use assets		2,872		694
Equity investments		1,680		2,155
Debt investment		2,219		2,000
Deferred tax asset		4,558		3,119
Identifiable intangibles, net		567		—
Goodwill		29,765		—
Other long-term assets		887		1,590
Total long-term assets		116,528		77,301
TOTAL ASSETS	$	154,895	$	117,043

LIABILITIES
Current liabilities
Trade payables	$	4,180	$	2,650
Deferred revenue		6,207		4,624
Income taxes payable		2,153		—
Accrued liabilities		17,578		11,092
Finance lease liabilities, current portion		256		—
Operating lease liabilities, current portion		678		495
Current debt		1,072		—
Total current liabilities	$	32,124	$	18,861
Long-term liabilities
Accrued liabilities		558		889
Finance lease liabilities, less current portion		132		—
Operating lease liabilities, less current portion		2,184		199
Long-term debt		6,002		—
Total long-term liabilities	$	8,876	$	1,088
TOTAL LIABILITIES	$	41,000	$	19,949

Commitments and Contingencies		—		—

SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,506,161 and 38,049,739 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively		18,702		15,123
Additional paid-in capital		15,698		12,125
Retained earnings		79,495		69,846
TOTAL SHAREHOLDERS' EQUITY	$	113,895	$	97,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	154,895	$	117,043

Viemed Healthcare, INC. CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME *(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)*
	Three Months Ended December 31,						Year Ended December 31,
		2023			2022			2023			2022
Revenue	$	50,739		$	37,508		$	183,008		$	138,832

Cost of revenue		18,628			14,612			70,225			54,152

Gross profit	$	32,111		$	22,896		$	112,783		$	84,680

Operating expenses
Selling, general and administrative		23,905			17,172			87,884			68,161
Research and development		651			722			2,782			2,696
Stock-based compensation		1,534			1,317			5,849			5,202
Depreciation and amortization		434			241			1,391			1,012
Loss on disposal of property and equipment		272			178			645			346
Other income, net		26			(268	)		(98	)		(989	)
Income from operations	$	5,289		$	3,534		$	14,330		$	8,252

Non-operating income and expenses
Income from equity method investments		43			82			485			935
Interest expense, net		(256	)		(32	)		(424	)		(197	)

Net income before taxes		5,076			3,584			14,391			8,990
Provision for income taxes		1,599			1,146			4,148			2,768

Net income	$	3,477		$	2,438		$	10,243		$	6,222

Other comprehensive income
Change in unrealized gain/loss on derivative instruments, net of tax		—			(56	)		—			278
Other comprehensive income	$	—		$	(56	)	$	—		$	278

Comprehensive income	$	3,477		$	2,382		$	10,243		$	6,500

Net income per share
Basic	$	0.09		$	0.06		$	0.27		$	0.16
Diluted	$	0.09		$	0.06		$	0.25		$	0.16

Weighted average number of common shares outstanding:
Basic		38,492,731			38,015,795			38,354,071			38,655,403
Diluted		40,383,109			39,513,158			40,378,922			39,807,434

Viemed Healthcare, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS *(Expressed in thousands of U.S. Dollars)*
	Year Ended December 31,
		2023			2022
Cash flows from operating activities
Net income	$	10,243		$	6,222
Adjustments for:
Depreciation and amortization		21,862			15,630
Change in inventory reserve		—			(1,418	)
Stock-based compensation expense		5,849			5,202
Distributions of earnings received from equity method investments		980			1,079
Income from equity method investments		(485	)		(935	)
Income from debt investment		(219	)		—
Loss on disposal of property and equipment		645			346
Deferred income tax (benefit) expense		(1,439	)		1,746
Changes in working capital, net of effects from acquisitions:
Accounts receivable, net		(1,058	)		(2,556	)
Inventory		(472	)		301
Prepaid expenses and other assets		2,176			(2,838	)
Trade payables		(859	)		(318	)
Deferred revenue		851			871
Accrued liabilities		4,959			2,549
Income tax payable/receivable		2,179			1,867
Net cash provided by operating activities	$	45,212		$	27,748

Cash flows from investing activities
Purchase of property and equipment		(26,093	)		(22,898	)
Investment in equity investments		(20	)		(141	)
Cash paid for acquisition of HMP, net of cash acquired		(28,588	)		—
Investment in debt security		—			(2,000	)
Proceeds from sale of property and equipment		2,588			1,063
Net cash used in investing activities	$	(52,113	)	$	(23,976	)

Cash flows from financing activities
Proceeds from exercise of options		1,303			283
Proceeds from term notes		5,000			—
Principal payments on term notes		(3,721	)		(5,796	)
Proceeds from revolving credit facilities		8,000			—
Payments on revolving credit facilities		(7,005	)		—
Shares redeemed to pay income tax		(594	)		(143	)
Shares repurchased under the share repurchase program		—			(9,568	)
Repayments of lease liabilities		(157	)		(42	)
Net cash provided by (used in) financing activities	$	2,826		$	(15,266	)

Net decrease in cash and cash equivalents		(4,075	)		(11,494	)
Cash and cash equivalents at beginning of year		16,914			28,408
Cash and cash equivalents at end of period	$	12,839		$	16,914

Supplemental disclosures of cash flow information
Cash paid during the period for interest	$	851		$	231
Cash paid (received) during the period for income taxes, net of refunds	$	3,566		$	(846	)
Supplemental disclosures of non-cash transactions
Non-cash change in debt from the reclassification of debt issuance costs	$	(594	)	$	—
Net non-cash changes to operating lease	$	(41	)	$	530

Viemed Healthcare, INC. Reconciliation of Net Income to Non-GAAP Adjusted EBITDA *(Expressed in thousands of U.S. Dollars)* *(Unaudited)*
For the quarter ended	December 31, 2023		September 30, 2023		June 30, 2023			March 31, 2023			December 31, 2022		September 30, 2022		June 30, 2022		March 31, 2022
Net Income	$	3,477	$	2,919	$	2,330		$	1,517		$	2,438	$	1,055	$	967	$	1,762
Add back:
Depreciation & amortization		5,918		5,975		5,207			4,762			4,373		4,120		3,740		3,397
Interest expense (income)		256		237		(20	)		(49	)		32		42		59		64
Stock-based compensation ^(a)		1,534		1,453		1,471			1,391			1,317		1,309		1,271		1,305
Transaction costs ^(b)		61		177		94			206			—		—		—		—
Income tax expense		1,599		1,320		728			501			1,146		456		421		745
Adjusted EBITDA	$	12,845	$	12,081	$	9,810		$	8,328		$	9,306	$	6,982	$	6,458	$	7,273

	Year Ended December 31, 2023
Net Income	$	10,243
Add back:
Depreciation & amortization		21,862
Interest expense (income)		424
Stock-based compensation ^(a)		5,849
Transaction costs ^(b)		538
Income tax expense		4,148
Adjusted EBITDA	$	43,064

(in thousands)	Three Months Ended December 31,						Year Ended December 31,
		2023			2022			2023			2022
Net cash provided by operating activities	$	13,284		$	7,684		$	45,212		$	27,748
Purchase of property and equipment		(7,932	)		(5,572	)		(26,093	)		(22,898	)
Free Cash Flow	$	5,352		$	2,112		$	19,119		$	4,850

Viemed Healthcare, INC. Key Financial and Operational Information *(Expressed in thousands of U.S. Dollars, except vent patients)* *(Unaudited)*
For the quarter ended	December 31, 2023			September 30, 2023			June 30, 2023			March 31, 2023			December 31, 2022			September 30, 2022			June 30, 2022			March 31, 2022
Financial Information:
Revenue	$	50,739		$	49,402		$	43,311		$	39,556		$	37,508		$	35,759		$	33,310		$	32,255
Gross Profit		32,111			30,562			26,106			24,004			22,896			21,651			20,390			19,743
Gross Profit %		63	%		62	%		60	%		61	%		61	%		61	%		61	%		61	%
Net Income		3,477			2,919			2,330			1,517			2,438			1,055			967			1,762
Cash and Cash Equivalents (As of)		12,839			10,078			10,224			23,544			16,914			21,478			21,922			29,248
Total Assets (As of)		154,895			149,400			149,117			124,634			117,043			119,419			115,904			119,007
Adjusted EBITDA ⁽¹⁾		12,845			12,081			9,810			8,328			9,306			6,982			6,458			7,273
Operational Information:
Vent Patients ⁽²⁾		10,327			10,244			10,005			9,337			9,306			9,127			8,837			8,434

TSX Venture Exchange Stock Maintenance Bulletins

1. UnitedHealth Group (NYSE:UNH)

2. Thermo Fisher Scientific (NYSE:TMO)

3. Abbott Laboratories (NYSE:ABT)

4. Intuitive Surgical (NASDAQ:ISRG)

5. Stryker (NYSE:SYK)

Latest News

Latest Press Releases

Related News

TOP STOCKS